These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 32601077)

  • 1. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
    Martín-Broto J; Moura DS; Van Tine BA
    Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
    Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
    Front Immunol; 2021; 12():775761. PubMed ID: 34925348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
    Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
    Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Targeted and Immune-Based Therapies in Sarcoma.
    Pollack SM; Ingham M; Spraker MB; Schwartz GK
    J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
    Zhu MMT; Shenasa E; Nielsen TO
    Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.
    Seong G; D'Angelo SP
    Front Oncol; 2023; 13():1150765. PubMed ID: 37007160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention.
    Tazzari M; Bergamaschi L; De Vita A; Collini P; Barisella M; Bertolotti A; Ibrahim T; Pasquali S; Castelli C; Vallacchi V
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next frontiers in systemic therapy for soft tissue sarcoma.
    Yen CC; Chen TW
    Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of immunotherapy for sarcomas.
    Miwa S; Nishida H; Tsuchiya H
    Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
    Banks LB; D'Angelo SP
    J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in Sarcoma: Current Data and Promising Strategies.
    Wood GE; Meyer C; Petitprez F; D'Angelo SP
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Sarcoma: Future Horizons.
    Burgess M; Gorantla V; Weiss K; Tawbi H
    Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soft tissue sarcoma as a model disease to examine cancer immunotherapy.
    Maki RG
    Curr Opin Oncol; 2001 Jul; 13(4):270-4. PubMed ID: 11429485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and translational implications of immunotherapy in sarcomas.
    Recine F; Vanni S; Bongiovanni A; Fausti V; Mercatali L; Miserocchi G; Liverani C; Pieri F; Casadei R; Cavaliere D; Falbo PT; Diano D; Ibrahim T; De Vita A
    Front Immunol; 2024; 15():1378398. PubMed ID: 38983859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.
    Smith SM; Iwenofu OH
    Chin Clin Oncol; 2018 Aug; 7(4):44. PubMed ID: 30173534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.